L. Hawkins

发表

Consequences of Interaction of a Lipophilic Endotoxin Antagonist with Plasma Lipoproteins

D. Rossignol, W. Christ, K. Wasan, 2000, Antimicrobial Agents and Chemotherapy.

Preclinical efficacy of an anti‐methamphetamine vaccine using E6020 adjuvant

R. Arora, T. Kosten, T. Kosten, 2019, The American journal on addictions.

A Novel Synthetic Acyclic Lipid A-like Agonist Activates Cells via the Lipopolysaccharide/Toll-like Receptor 4 Signaling Pathway*

F. Gusovsky, D. Golenbock, K. Miyake, 2001, The Journal of Biological Chemistry.

Toll-like receptor 2 antagonists. Part 1: preliminary SAR investigation of novel synthetic phospholipids.

Jesse C. Chow, M. Spyvee, Huiming Zhang, 2005, Bioorganic & medicinal chemistry letters.

A novel class of endotoxin receptor agonists with simplified structure, toll-like receptor 4-dependent immunostimulatory action, and adjuvant activity.

F. Gusovsky, Han Yang, D. Rossignol, 2002, The Journal of pharmacology and experimental therapeutics.

Design and preclinical characterization of a novel vaccine adjuvant formulation consisting of a synthetic TLR4 agonist in a thermoreversible squalene emulsion.

J. Haensler, N. Burdin, Jean-François Cotte, 2015, International journal of pharmaceutics.

THE INDUCTION OF SUPER-RESISTANCE USING SYNTHETIC LIPOPOLYSACCHARIDE RECEPTOR AGONIST RESCUES FATAL ENDOTOXEMIA IN RATS WITHOUT EXCESSIVE IMMUNOSUPPRESSION

K. Mafune, M. Kaminishi, M. Muroi, 2005, Shock.

Association of the Endotoxin Antagonist E5564 with High-Density Lipoproteins In Vitro: Dependence on Low-Density and Triglyceride-Rich Lipoprotein Concentrations

D. Rossignol, W. Christ, K. Wasan, 2003, Antimicrobial Agents and Chemotherapy.

Lipoprotein Distribution of a Novel Endotoxin Antagonist, E5531, in Plasma from Human Subjects with Various Lipid Levels

D. Rossignol, W. Christ, K. Wasan, 1999, Antimicrobial Agents and Chemotherapy.

Levels from Human Subjects with Various Lipid Endotoxin Antagonist , E 5531 , in Plasma Lipoprotein Distribution of a Novel

D. Rossignol, W. Christ, K. Wasan, 1999 .

The generalized endotoxic principle

M. Koch, H. Heine, K. Brandenburg, 2003, European journal of immunology.

Novel synthetic LPS receptor agonists boost systemic and mucosal antibody responses in mice.

S. Ishizaka, Jesse C. Chow, H. Cheng, 2003, Vaccine.

What can calorimetry tell us about changes of three-dimensional aggregate structures of phospholipids and glycolipids?

M. Koch, K. Brandenburg, U. Seydel, 2006 .

Trends in synthetic carbohydrate chemistry

D. Horton, G. Mcgarvey, L. Hawkins, 1989 .

Building C(sp3)-rich Complexity by Combining Cycloaddition and C–C Cross Coupling Reactions

Hui Fang, Yutong Lin, Phil S. Baran, 2018, Nature.

Total Synthesis of Palytoxin Carboxylic Acid and Palytoxin Amide

W. Christ, R. W. Armstrong, H. Fujioka, 1989 .

Total Synthesis of the Proposed Structure of Rhodobacter sphaeroides Lipid A Resulting in the Synthesis of New Potent Lipopolysaccharide Antagonists

A. Robidoux, W. Christ, Y. Wang, 1994 .

Structurally simplified macrolactone analogues of halichondrin B.

Melvin J. Yu, Y. Wang, M. Towle, 2004, Bioorganic & medicinal chemistry letters.

E5531, a pure endotoxin antagonist of high potency.

A. Robidoux, W. Christ, M. Perez, 1995, Science.

Structural polymorphism and endotoxic activity of synthetic phospholipid-like amphiphiles.

M. Koch, H. Heine, K. Brandenburg, 2004, Biochemistry.

Synthetic Toll-Like Receptor 4 Agonist Enhances Vaccine Efficacy in an Experimental Model of Toxic Shock Syndrome

S. Ishizaka, T. Kissner, R. Ulrich, 2007, Clinical and Vaccine Immunology.

Modulators of Toll-Like Receptor (TLR) Signaling

S. Ishizaka, M. Spyvee, L. Hawkins, 2010 .

Dissociation of TRIF bias and adjuvanticity.

S. Vogel, Wendy Lai, R. Ernst, 2020, Vaccine.

Respiratory Syncytial Virus Fusion Protein-Induced Toll-Like Receptor 4 (TLR4) Signaling Is Inhibited by the TLR4 Antagonists Rhodobacter sphaeroides Lipopolysaccharide and Eritoran (E5564) and Requires Direct Interaction with MD-2

M. Boukhvalova, S. Vogel, J. Weiss, 2012, mBio.

Effective antibody therapy induces host-protective antitumor immunity that is augmented by TLR4 agonist treatment

L. Weiner, M. Mehren, Wei Xu, 2011, Cancer Immunology, Immunotherapy.

MF59 Emulsion Is an Effective Delivery System for a Synthetic TLR4 Agonist (E6020)

Manmohan J. Singh, B. Baudner, A. Wack, 2009, Pharmaceutical Research.

E6020: a synthetic Toll-like receptor 4 agonist as a vaccine adjuvant

S. Ishizaka, L. Hawkins, 2007, Expert review of vaccines.

Hemoglobin enhances the biological activity of synthetic and natural bacterial (endotoxic) virulence factors: a general principle.

A. Ulmer, E. Rietschel, H. Brade, 2008, Medicinal chemistry (Shariqah (United Arab Emirates)).

Inhibition of endotoxin response by synthetic TLR4 antagonists.

D. Rossignol, W. Christ, L. Hawkins, 2004, Current topics in medicinal chemistry.

E6020, a TLR4 Agonist Adjuvant, Enhances Both Antibody Titers and Isotype Switching in Response to Immunization with Hapten-Protein Antigens and Is Diminished in Mice with TLR4 Signaling Insufficiency

S. Vogel, M. Sztein, R. Wahid, 2022, The Journal of Immunology.

A novel Toll-like receptor 7/8-specific antagonist E6742 Ameliorates clinically relevant disease parameters in murine models of lupus.

S. Ishizaka, Qian Chen, Toshiyuki Shimizu, 2023, European journal of pharmacology.

Anti-endotoxin activity of a novel synthetic lipid A analog.

D. Rossignol, W. Christ, Y. Kishi, 1995, Progress in clinical and biological research.

MF59 oil-in-water emulsion in combination with a synthetic TLR4 agonist (E6020) is a potent adjuvant for a combination Meningococcus vaccine

M. Pizza, M. Giuliani, Manmohan J. Singh, 2012, Human vaccines & immunotherapeutics.